Gene therapy – once just a dream, now a reality
Authors:
Radim Brdička 1; Milan Macek jr. 1; Karolina Veberová Brdičková 2
Authors place of work:
Ústav biologie a lékařské genetiky 2. LF UK a FN Motol, Praha
1; Biogen Praha, s. r. o.
2
Published in the journal:
Čas. Lék. čes. 2024; 163: 87-93
Category:
Review Article
Summary
Gene therapy is gradually becoming a mainstream treatment modality and is no longer the preserve of large university departments whose laboratories master nucleic acid analytical procedures and whose clinical teams manage its administration. It was originally designed for genetic diseases that, because of their prevalence, were a group known as rare diseases. Gene therapy has so far been applied in children to act before the disease development. These new treatments have also begun to be applied for common diseases such as metabolic disorders (e. g. diabetes) and even for those that are increasingly affecting us, such as various malignancies and diseases of the central nervous system (e. g. Alzheimer’s disease).
The targets targeted by GT are genes, where pathogenic alterations in the form of pathogenic variants (formerly mutations) induce phenotypic disorders, and our aim is either to knock them out of function (e. g. haemoglobinopathies) or to replace them with genes with normal function, which we introduce into the genome using one of the appropriate vectors, such as viruses or liposomes. The process of GT can take place directly inside the patient's body (in vivo) or outside the body on isolated cells (ex vivo), which are usually stem cells (iPSCs, induced pluripotent stem cell). After treatment, these cells are returned to the patient's body to fulfil their "destiny". In a broader sense, GT can target the product of gene transcription, which is the messenger RNA, or the end product of gene function, such as functional proteins (eg. cystic fibrosis).
Any of these approaches have been used successfully in various diseases, depending on their availability, which is determined, among other things, by the costs associated with GT or the accessibility of the target tissue. Ultimately, it is not only the validation of the efficacy and safety of GT, but also economic reasons that determine why GT has been slow to develop and is mostly undertaken only by large and wealthy institutions. Another decisive factor is that from initial experimental work through clinical trials, the whole process of its development normally takes up to a decade.
Keywords:
gene therapy, rare diseases, common diseases, cancer
Zdroje
- Wolff JH, Mikkelsen JG. Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years. J Biomed Sci 2022; 29: 79.
- Kohn DB. Gene therapy for blood diseases. Curr Opin Biotechnol 2019; 60: 39–45.
- Sheridan C. The world’s first CRISPR therapy is approved: who will receive it? Nat Biotechnol 2024; 42: 3–4.
- Frangoul H, Bobruff Y, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med 2021; 384: 252–260.
- Breda L, Papp TE, Triebwasser MP et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 2023; 381: 436–443.
- Nathwani AC. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program 2019; 2019: 1–8.
- Miesbach W, Klamroth R, Oldenburg J, Tiede A. Gene therapy for hemophilia – opportunities and risks. Dtsch Arztebl Int 2022; 119: 887–894.
- Goetz DM , Savant AP. Review of CFTR modulators 2020 Pediatr Pulmonol 2021; 56: 3595–3606.
- Boyd AC, Guo S, Huang L et al. New approaches to genetic therapies for cystic fibrosis. J Cyst Fibros 2020; Suppl. 1: S54–S59
- King JA, Nichols A L, Bentley S et al. An Update on CFTR modulators as new therapies for cystic fibrosis. Paediatr Drugs 2022; 24, 321–333.
- Allen L, Allen L, Carr SB et al. Future therapies for cystic fibrosis. Nat Commun 2023; 14: 693.
- Xu W, WuT, Zhou Z, Zuo Z. Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis. Front Pharmacol 2023; 14: 1275470.
- Lomunova MA, Gershovich PM. Gene therapy for cystic fibrosis: recent advances and future prospects. Acta Naturae 2023; 15: 20–31.
- Pires Ferreira D, Gruntman AM, Flotte TR. Gene therapy for alpha-1 antitrypsin deficiency: an update. Expert Opin Biol Ther 2023; 23: 283–291.
- Strnad P, Mandorfer M, Choudhury G et al. Fazirsiran for liver disease associated with alpha1-antitrypsin deficiency. N Engl J Med 2022; 387: 514–524.
- Nowak I, Madej M, Secemska J et al. Virus-based biological systems as next-generation carriers for the therapy of central nervous system diseases. Pharmaceutics 2023; 15: 1931.
- Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci 2007; 30: 575–621.
- Durai S, Mani M, Kandavelou K et al. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res 2005; 33 (18): 5978–5990.
- Mittelman D, Moye Ch, Morton J et al. Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells. Proc Natl Acad Sci U S A 2009; 106: 9607–9612.
- López-Morató M, Brook J, Wojciechovska M. Small molecules which improve pathogenesis of myotonic dystrophy type 1. Front Neurol 2018; 9: 349.
- Byun S, Lee M, Kim M. Gene therapy for Huntington’s disease: the final strategy for a Cure? J Mov Disord 2022; 15: 15–20.
- Ikenoshita S, Matsuo K, Yabuki Y. A cyclic pyrrole-imidazole polyamide reduces pathogenic RNA in CAG/CTG triplet repeat neurological disease models. J Clin Invest 2023; 133: e164792
- Moore NA, Morral N, Ciulla TA et al. Gene therapy for inherited retinal and optic nerve degenerations. Expert Opin Biol Ther 2018; 18: 37–49.
- Chien WW, Monzack EL, McDougald DS et al. Gene therapy for sensorineural hearing loss. Ear Hear 2015; 36: 1–7.
- Amariutei AE. Recent advances and future challenges in gene therapy for hearing loss. R Soc Open Sci 2023; 10: 230644.
- Cameau E, Glover C, Pedregal A. Cost modelling comparison of adherent multi-trays with suspension and fixed-bed bioreactors for the manufacturing of gene therapy products. Cell Gene Therapy Insights 2019; 5 (11): 1663–1674.
- Moss T, LeDoux MS, Crane-Robinson C. HMG-boxes, ribosomopathies and neurodegenerative disease. Front Genet 2023; 14.
- Lyu S-Y, Xiao W, Cui G-Z, et al. Role and mechanism of DNA methylation and its inhibitors in hepatic fibrosis. Front Genet 2023; 14: 124330.
- Nilsson P, Iwata N, Muramatsu Sh et al. Gene therapy in Alzheimer’s disease – potential for disease modification. J Cell Mol Med 2010; 14: 741–757.
- Griciuc A, Federico AN, Natasan J et al. Gene therapy for Alzheimer’s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum Mol Genet 2020; 29: 2920–2935.
- Mummery CJ, Börjesson-Hanson A, Blackburn DJ et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nat Med 2023; 29: 1437–1447.
- Wong MS, Hawthorne WJ, Manolios N. Gene therapy i n diabetes. Self Nonself 2010; 1: 165–175.
- Srinivasan M, Thangaraj SR, Arzoun H. Gene therapy – can it cure type 1 diabetes? Cureus 2021; 13: e20516.
- Liang Z, Sun D, Lu, S. et al. Implementation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets. Nat Metab 2023; 5: 29–40.
- Keymeulen B, De Groot K, Jacobs-Tulleneers-Thevissen D et al. Encapsulated stem cell-derived β cells exert glucose control in patients with type 1 diabetes. Nat Biotechnol 2023, doi: 10.1038/s41587-023-02055-5.
- Casana E, Jimenez V, Jambrin C et al. AAV-mediated BMP7 gene therapy counters insulin resistance and obesity. Mol Ther Methods Clin Dev 2022; 25: 190–204.
- Ledford H. CRISPR cancer trial success paves the way for personalized treatments. Nature 2022; 611: 433–434.
- Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol 2020; 10: 1387.
- Rosenberg SA. Gene Therapy for cancer. JAMA 1992; 268: 2416–2419.
- Amer MH. Gene therapy for cancer: present status and future perspective. Mol and Cell Ther 2014; 2: 27.
- Španielová H, Brdička R. Onkolytické viry a léčení nádorového bujení. Klin Onkol 2023; 36: 12–28.
- Danielová K. Úloha a mechanismy působení buněk vrozené imunity při rozpoznávání a likvidaci nádorových buněk. Přírodovědecká fakulta JU, České Budějovice, 2019.
- Kaiser J. Modified T cells that attack leukemia become first gene therapy approved in the United States. Approval of Novartis cancer drug is "historic", FDA says. Science, 2017. Dostupné na: www.science.org/content/article/modified-t-cells-attack-leukemia-become-first-gene-therapy-approved-united-states
- Ottaviano G, Georgiadis C, Gkazi SA et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia Sci Transl Med 2022; 14: eabq3010.
- Wierda WG, Cantwell MJ, Woods SJ et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917–2924.
- Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clin Haematol 2011; 24: 147–163.
- Yakoub-Agha I, Chabannon C, Bader P et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 2020; 105: 297–316.
- Lara-Guerra H, Roth J. Gene therapy for lung cancer. Crit Rev Oncog 2016; 21(1–2): 115–124.
- Viola JR, Rafael DF, Wagner E et al. Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acid. J Drug Deliv 2013; Article ID 897348,
- Hromic-Jahjefendic A, Lundstrom K. Viral vector-based melanoma gene therapy. Biomedicines 2020; 8: 60.
- Bieńkowska-Tokarczyk A, Stelmaszczyk-Emmel A, Demkow U et al. Hyperthermia enhances adeno-associated virus vector transduction efficiency in melanoma cells. Curr Issues Mol Biol 2023; 45: 8519–8538.
- Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Sig Transduct Target Ther 2023; 8: 156.
- Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27–36.
- Pathak A, Tomar S, Pathak S. Epigenetics and cancer: a comprehensive review. Asian Pacific J Cancer Biol 2023; 8: 75–89.
- Fu MP, Merrill SM, Sharma M et al. Rare diseases of epigenetic origin: Challenges and opportunities. Front Genet 2023; 14: 1113086.
- Rohner E, Yang R, Foo KS et al. Unlocking the promise of mRNA therapeutics. Nat Biotechnol 2022; 40: 1586–1600.
- Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 2024; 403: 1192–1204.
- Hofman CR, Corey DR. Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges. Cell Chem Biol 2024; 31: 125–138.
- Liu D, Meyer D, Fennessy B, et al. Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations. Nat Genet 2023; 55: 369–376.
- Nakamura T, Takata A. The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research. Mol Psychiatry 2023; 28: 1868–1889.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Gene therapy – once just a dream, now a reality
- Ethical dimensions in telemedicine – balancing technology, responsible care, and patient protection
- Renal impairment in monoclonal gammopathies and multiple myeloma
- Risk factors for postoperative pneumonia in patients after lung resection for non-small cell lung cancer – results of a cohort study